The KEYNOTE-158 study (Chung et al., 2019) reported the objective response rates (ORRs) for pembrolizumab as 12.2% in all recurrent or metastatic cervical cancer patients and 14.3% in PD-L1–positive patients who had previously received chemotherapy. The gene discussed is CD274; the disease is cervical carcinoma.